Alexion Pharmaceuticals, Inc. (ALXN)
82
  • CONTENT
  • SOURCES
Alexion' Ultomiris ok'd in Japan (NASDAQ:ALXN)
Japan’s Ministry of Health, Labour and Welfare has approved Alexion Pharmaceuticals' (NASDAQ:ALXN) Ultomiris (ravulizumab) for atypical hemolytic uremic sy
European advisory group backs new formulation of Alexion's Ultomiris (NASDAQ:ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) announces that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending
A Look Into Alexion Pharmaceuticals's Price Over Earnings
In the current session, Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) is trading at $108.21, after a 2.71% spike. Over the past …
GOLDMAN SACHS: Buy these 9 stocks that are poised to continue crushing the market as the ‘shared favorites’ of Wall Street’s biggest investors
Ongoing economic uncertainty and low yields can make it difficult for investors to decide where to put their money. Goldman Sachs recently analyzed the stock holdings of 815 hedge funds and 572 mutual funds to uncover the companies that both groups own the most. The firm's basket of "shared favorites" has a track record of beating the market, and it has outperformed the S&P 500 since the March bottom. Click here to sign up for our weekly newsletter Investing Insider . Visit Business Insider's homepage for more stories . In a market environment with high volatility, ongoing economic uncertainty, low bond yields , and slashed dividends, it can be difficult to decide where to put your money. There are expert opinions to listen to, although one can often find contradicting assessments. But Goldman Sachs' quarterly Hedge Fund Trend Monitor and Mutual Fundamentals reports can often be sources of much-sought-after consensus. The investment bank recently published a note that analyzed the top holdings of 815 hedge funds and 572 mutual funds.
Alexion hires first chief diversity officer, following pharma peers and social sentiment
Alexion Pharmaceuticals names its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion. The company joins a majority of Big Pharma with C-level execs focusing on diversity, particularly relevant in the current social climate—and as white men still dominate top positions across the industry.
3 Covid-Proof Plays Not Named Amazon or Apple
Tutor Perini (TPC), Beazer Homes (BZH) and Alexion Pharmaceuticals (ALXN) are three Covid-proof stocks that all turned in solid results in the face of the pandemic….TPC
Strength in Alexion Pharmaceuticals May Be Temporary
Strength in Alexion Pharmaceuticals May Be a Temporary…ALXN
Inozyme buys ENPP1 deficiency program assets from Alexion (Pending:INZY)
Inozyme Pharma (INZY) acquires intellectual property and assets focusing on ENPP1 gene deficiencies, from Alexion Pharmaceuticals (NASDAQ:ALXN). Inozyme sa
Alexion Pharmaceuticals: Growth At A Reasonable Price (GARP)
Introduction I find it very interesting that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) after going public in 2001, did not generate their first profit until December 2008. As we all know, this was in the throes of what is now known as the Great Recession of 2008. Moreover, Alexion’s adjusted operating earnings have grown from $0.20 per […] The post Alexion Pharmaceuticals: Growth At A Reasonable Price (GARP) appeared first on ValueWalk .
Alexion Pharmaceuticals Agrees to $21.5 Million Settlement With SEC in Bribery Case | The Motley Fool
The company was accused of making improper payments to government officials in Turkey and Russia.
Top 6 Biotech Stocks For Traders
If you’re up for some speculative biotech trades, we are presenting the top 6 among our freshest picks of biotech stocks for the coming 12 months.
Follow Us